MedTrace Logo

Evaluation of the Safety of Cytokine-Induced-Killer Cells During Early Transplant Period of Autologous Hematopoietic Stem Cell Transplant Recipients.

NCT07692607 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-07-09

No results posted yet for this study

Summary

The goal of this clinical study is to evaluate the safety of cytokine-induced-killer (CIK) cells during early transplant period of autologous hematopoietic stem cell transplant. The main questions it aims to answer are:

* What adverse events occur within 2 years following CIK infusion?
* Does viral reactivation (CMV, EBV, BKV) occur and lead to infection during the early transplant period of autologous hematopoietic stem cell transplant after CIK infusion?

Patients will:

* Receive a single infusion of CIK at a dose of 1x10\^9 to 1x10\^10 cells either intravenously or using a central venous catheter within 14±4 days after receiving the autologous hematopoietic stem cell transplantation.
* Attend follow-up visits at the clinic for 24 months after the infusion.

Conditions

  • Autologous Hematopoietic Stem Cell Transplant

Interventions

BIOLOGICAL

CIK cells

Derived from the patient (autologous) prior to autologous hematopoietic stem cell transplantation and administered intravenously as fresh cells at a dose of 1x10\^9 to 1x10\^10 cells over 30 minutes.

Sponsors & Collaborators

  • LucasBio

    lead INDUSTRY

Principal Investigators

  • Seok-Goo Cho, MD-PhD · Department of Hematology, The Catholic University of Korea Seoul St.Mary's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-28
Primary Completion
2025-02-11
Completion
2026-03-17

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07692607 on ClinicalTrials.gov